Literature DB >> 15967652

Development of an enteric-coated, layered multi-particulate formulation for ileal delivery of viable recombinant Lactococcus lactis.

Nathalie Huyghebaert1, An Vermeire, Pieter Rottiers, Erik Remaut, Jean Paul Remon.   

Abstract

Layering of recombinant hIL-10 producing Lactococcus lactis (L. lactis Thy12) on inert carriers is a promising technique for the preparation of a multi-particulate formulation of viable, hIL-10 producing L. lactis. To improve viability after layering and storage, L. lactis Thy12 was layered in different matrices (10% skim milk and/or 2.5, 5, 10% inulin). After layering, the highest viability was obtained in the 10% skim milk supplemented with 5% inulin matrix (8.7%). However, upon storage, 10% skim milk alone yielded the highest viability. Thereby, layered L. lactis Thy12 showed superior long term stability in comparison with freeze-dried L. lactis Thy12. The layering process was performed during 3h without encountering technical problems, with good layer consistence and constant viability. Enteric properties were obtained with a 30% Eudragit L30D-55 or 15% Eudragit FS30D coating and maintained during an initial six months storage period (-20 degrees C/20% RH). After in vitro simulation of the gastric stage, only 5% of the bacteria remained viable in Eudragit L30D-55 coated pellets, contrary to 85% in Eudragit FS30D coated pellets, indicating its superior protective capacity against gastric fluid. After eight months storage (-20 degrees C), 80% of the initial L. lactis Thy12 remained viable in the Eudragit FS30D coated pellets.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15967652     DOI: 10.1016/j.ejpb.2005.04.002

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  5 in total

1.  Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit.

Authors:  Katleen Broos; Michiel E Janssens; Ine De Goeyse; Peter Vanlandschoot; Geert Leroux-Roels; Dirk Geysen; Yves Guisez
Journal:  Clin Vaccine Immunol       Date:  2008-03-26

2.  Adenosine 5'-triphosphate (ATP) supplements are not orally bioavailable: a randomized, placebo-controlled cross-over trial in healthy humans.

Authors:  Ilja Cw Arts; Erik Jcm Coolen; Martijn Jl Bours; Nathalie Huyghebaert; Martien A Cohen Stuart; Aalt Bast; Pieter C Dagnelie
Journal:  J Int Soc Sports Nutr       Date:  2012-04-17       Impact factor: 5.150

Review 3.  Development of microencapsulation delivery system for long-term preservation of probiotics as biotherapeutics agent.

Authors:  Himanshu K Solanki; Dipak D Pawar; Dushyant A Shah; Vipul D Prajapati; Girish K Jani; Akil M Mulla; Prachi M Thakar
Journal:  Biomed Res Int       Date:  2013-08-21       Impact factor: 3.411

4.  Targeted Release of Probiotics from Enteric Microparticulated Formulations.

Authors:  Cristina Yus; Ruben Gracia; Ane Larrea; Vanesa Andreu; Silvia Irusta; Victor Sebastian; Gracia Mendoza; Manuel Arruebo
Journal:  Polymers (Basel)       Date:  2019-10-13       Impact factor: 4.329

Review 5.  Lactococcus lactis As a Versatile Vehicle for Tolerogenic Immunotherapy.

Authors:  Dana P Cook; Conny Gysemans; Chantal Mathieu
Journal:  Front Immunol       Date:  2018-01-17       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.